NEW ORLEANS

新奥尔良

,

，

Sept. 10, 2026

2026年9月10日

/PRNewswire/ -- LongueVue Capital ('LVC') is pleased to announce that its portfolio company, Summit Clinical Research Solutions ('Summit' or the 'Company'), an integrated clinical research organization designed to simplify sponsor engagement and accelerate trial execution across the clinical development lifecycle, has acquired Dallas Research Institute ('DRI') through its integrated site network, Pinnacle Clinical Research ('Pinnacle').

/美通社/ -- LongueVue Capital（“LVC”）欣然宣布，其投资组合公司 Summit Clinical Research Solutions（“Summit”或“该公司”）已通过其整合站点网络 Pinnacle Clinical Research（“Pinnacle”）收购 Dallas Research Institute（“DRI”）。Summit 是一家一体化临床研究组织，旨在简化申办方参与并加速整个临床开发生命周期中的试验执行。

The acquisition of DRI deepens Summit's expertise in metabolic and liver diseases and expands Pinnacle's presence in the Dallas-Fort Worth metroplex ('DFW'), a strategic MSA for Pinnacle..

收购DRI加深了Summit在代谢和肝脏疾病领域的专业知识，并扩大了Pinnacle在达拉斯-沃斯堡都市区（DFW）的影响力，该地区是Pinnacle的一个重要都会统计区。

Founded in 2024 as a joint venture between the late Dr. Stephen Harrison (co-founder of Summit and Pinnacle) and the Company, DRI specializes in complex clinical trials targeting metabolic and liver-related conditions, including Metabolic Dysfunction-Associated Steatotic Liver Disease ('MASLD') and Metabolic Dysfunction-Associated Steatohepatitis ('MASH'), and obesity.

DRI 成立于 2024 年，由已故的 Stephen Harrison 博士（Summit 和 Pinnacle 的联合创始人）与本公司共同成立的合资企业。DRI 专注于针对代谢和肝脏相关疾病（包括代谢功能障碍相关脂肪性肝病 [MASLD] 和代谢功能障碍相关脂肪性肝炎 [MASH]）以及肥胖症的复杂临床试验。

This focus aligns closely with Summit's core therapeutic expertise and adds a high-quality site in one of the largest, most diverse, and highest growth markets in the country where Pinnacle currently operates two additional sites. Dr. Pedro Castillo Jr., a double board-certified physician in Internal Medicine and Rheumatology, has served as the site's Principal Investigator ('PI') since its inception and will continue in his role post-closing..

这一战略重点与Summit的核心治疗专长高度契合，并在该国规模最大、最具多样性且增长最快的市场之一增加了一个高质量的研究站点；Pinnacle目前在该市场已运营另外两个站点。Pedro Castillo Jr.博士拥有内科和风湿病学的双重董事会认证医师资格，自该站点成立以来一直担任主要研究者（PI），并在交易完成后继续担任该职务。

'DRI is a natural fit for the Pinnacle site network given its overlapping therapeutic area focus and expands the Company's presence in the desirable DFW metroplex,' said Ryan Nagim, Managing Partner and Head of Healthcare at LVC. 'Since its inception, DRI was created consistent with Dr. Stephen Harrison's vision, making this a highly strategic and accretive acquisition.'.

LVC的管理合伙人兼医疗健康板块负责人Ryan Nagim表示：“鉴于治疗领域重点的重合，DRI与Pinnacle站点网络天然契合，并扩大了公司在备受青睐的达拉斯-沃斯堡大都市区的布局。自成立之初，DRI便秉承Stephen Harrison博士的愿景而创立，这使得此次收购具有高度的战略意义并能增厚公司价值。”

'From the beginning, it was clear that Summit and Pinnacle share our commitment to conducting high-quality clinical research and delivering exceptional patient care,' said Dr. Pedro Castillo Jr., Principal Investigator of DRI. 'We're excited to join an organization that will help us to continue to expand our impact on patients and provide industry leading solutions to sponsors while staying true to the values and culture that have defined DRI to date.'.

“从一开始，Summit 和 Pinnacle 就显然与我们一样，致力于开展高质量的临床研究并提供卓越的患者护理，”DRI 首席研究员 Pedro Castillo Jr. 博士表示。“我们很高兴加入一个能够帮助我们继续扩大对患者的影响、为申办方提供行业领先解决方案的组织，同时坚守迄今为止定义 DRI 的价值观和文化。”

LVC Managing Partner Ryan Nagim was assisted by Partner Austin Rees, Director Kent McCarty, Vice President Erin Saer, Senior Associate Rankin Hobbs, and Associate Alex Wisecarver.

LVC管理合伙人瑞安·纳吉姆在合伙人奥斯汀·里斯、总监肯特·麦卡蒂、副总裁艾琳·塞尔、高级助理兰金·霍布斯以及助理亚历克斯·怀斯卡弗的协助下开展工作。

To learn more about Summit, Pinnacle, and DRI, please visit:

如需了解更多关于 Summit、Pinnacle 和 DRI 的信息，请访问：

www.summitclinicalresearch.com

www.summitclinicalresearch.com

www.pinnacleresearch.com

www.pinnacleresearch.com

www.dallasresearchinstitute.com

www.dallasresearchinstitute.com

About Dallas Research Institute

关于达拉斯研究所

Located in DFW, DRI is a single-location clinical research site specializing in complex clinical trials, particularly those targeting metabolic diseases such as MASH and MASLD. DRI has developed strong relationships with pharmaceutical sponsors and is recognized for its exceptional patient recruitment capabilities and strong community engagement, supported by partnerships with local medical practices..

DRI 位于达拉斯-沃斯堡（DFW）地区，是一家单地点临床研究机构，专注于复杂临床试验，尤其是针对代谢相关脂肪性肝炎（MASH）和代谢相关脂肪性肝病（MASLD）等代谢性疾病的试验。DRI 与制药申办方建立了稳固的合作关系，并因其卓越的患者招募能力和深入的社区参与而广受认可，这得益于其与当地医疗机构的合作伙伴关系。

About Summit Clinical Research Solutions

关于 Summit 临床研究解决方案

Summit is an integrated clinical research organization delivering high-quality execution across the clinical trial lifecycle. Through its integrated site network ('Pinnacle'), global partner-site network and IRO services ('Elevation'), centralized recruitment platform ('Apogee'), medical communications and scientific strategy services ('Ascend'), and early-phase CRO capabilities ('Apex'), Summit helps sponsors accelerate and optimize clinical development.

Summit 是一家整合型临床研究组织，在临床试验全生命周期中提供高质量的执行服务。通过其整合站点网络（“Pinnacle”）、全球合作站点网络及独立审查机构（IRO）服务（“Elevation”）、中心化招募平台（“Apogee”）、医学传播与科学战略服务（“Ascend”）以及早期阶段合同研究组织（CRO）能力（“Apex”），Summit 助力申办方加速并优化临床开发。

Headquartered in San Antonio, Texas, Summit's platform spans more than 110 partner sites across eight countries and 15 fully owned sites across the US, with deep specialization in metabolic disease, MASH, obesity, and Alzheimer's disease. Since 2018, the Summit platform has supported more than 85 sponsors across 170+ clinical trials, with its affiliated sites consistently ranking among the top enrollers in their studies..

Summit 总部位于德克萨斯州圣安东尼奥，其平台覆盖遍布八个国家的110多个合作站点，以及在美国境内的15个全资站点，在代谢性疾病、代谢功能障碍相关脂肪性肝炎（MASH）、肥胖症和阿尔茨海默病领域拥有深厚的专业积累。自2018年以来，Summit 平台已在170多项临床试验中为85多家申办方提供支持，其旗下站点在患者入组方面始终位居前列。

About LongueVue Capital

关于 LongueVue Capital

Founded in 2001, LongueVue Capital is a New Orleans-based private equity investment firm focused on providing transformational growth capital to middle-market companies, drawing upon its successful 20+ year track record of partnering with entrepreneurs and management teams to drive value creation. With over $1 billion of committed capital spanning five funds coupled with 200+ years of combined operating and investing experience, LVC is an ideal partner for middle-market companies at inflection points seeking to maximize value for all stakeholders..

LongueVue Capital 成立于2001年，是一家总部位于新奥尔良的私募股权投资公司，专注于为中型企业提供变革性增长资本。凭借二十多年来与企业家和管理团队合作以推动价值创造的成功记录，LVC 已成为理想的合作伙伴。公司拥有五支基金，承诺资本总额超过10亿美元，团队合计拥有逾200年的运营和投资经验，是处于转折点的中型企业最大化所有利益相关方价值的理想伙伴。

For more information or media inquiries, please contact

如需更多信息或媒体垂询，请联系

[email protected]

[email protected]

or visit

或访问

www.lvcpartners.com

www.lvcpartners.com

.

。

SOURCE LongueVue Capital

来源：LongueVue Capital

21

二十一

%

%

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示